Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon

5 things to know about Republicans’ amended ACA replacement plan

Republicans leaders in Congress have reportedly agreed on a new version of their Affordable Care Act (ACA) repeal-and-replace plan, allowing states to opt out of ACA requirements such as essential health benefits and a ban on individually rating customers on the individual market. 

Combining 3D printing, special effects helps make surgical practice perfect

Practicing complex surgical procedures on cadavers can be expensive. In an article in Journal of Neurosurgery: Pediatrics, researchers outlined an improved method of practice for surgeons by combining 3D printing with special effects.

Thumbnail

Major medical groups, hospitals split on ending mandatory bundled payments

The move by CMS to delay mandatory bundled payments for cardiac and orthopedic care was widely supported by medical associations and health systems, judging by their comments to the agency, but some went further, calling for these initiatives from the prior administration be made into voluntary programs.

U.S. hospitals still seeing 1,500 malaria cases a year

The transmission of malaria among the general population in the U.S. hasn’t been an issue for nearly 60 years—but as NPR reports, it’s a different story in hospitals, where nearly 1,500 cases are seen each year involving people who have been traveling abroad.

Thumbnail

Cutting off ACA insurer subsidies would raise—not lower—federal healthcare spending

If the Trump administration’s goal is to lower federal healthcare spending, discontinuing cost-sharing reduction subsidies, or CSRs, to insurers under the Affordable Care Act (ACA) could backfire, according to an analysis from the Kaiser Family Foundation.

Small practices hope for Tom Price tweaks to MACRA

Physicians at smaller practices want to see one of their fellow physicians offer some regulatory help to make it easier for them to participate in the new payment tracks under the Medicare Access and CHIP Reauthorization Act (MACRA).

Thumbnail

Express Scripts likely to lose Anthem, its biggest customer

Pharmacy benefits manager Express Scripts said it will lose Anthem as a client when its current contract expires at the end of 2019, claiming it can’t agree to the price concessions Anthem has been demanding.

Medicaid lost $1 billion in savings to illegal medical cannabis

Cost efficiency is a major concern for any healthcare provider, always searching for a more affordable, effective method of treatment. Medicaid has not been able to cash in the savings after reported having lost out on $1 billion in saving on prescriptions if cannabis were legalized. 

Displaying 4713 - 4720 of 6647

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup